AVAH reports Q1 2026 results tomorrow morning against a backdrop that has just grown more complicated: CMS announced a six-month moratorium on new hospice and home health agency registrations, citing an active fraud crackdown. The stock is up 5.4% on the week and nearly 10% over the past month, but the regulatory news — published today with a top importance score — lands less than 24 hours before management steps up to the podium.
The earnings reaction history gives shorts little comfort going in. The most recent comparable print, March 19, saw the stock fall 5.6% on the day and a further 4.3% over the ensuing five sessions. The Q1 2026 result posted on May 7 produced a negligible move of less than 0.3%, suggesting the market either had the number well-priced or was waiting for the next catalyst. That next catalyst arrives tomorrow.
Short sellers have been retreating. Short interest dropped nearly 19% over the past week, falling to just 1.3% of the free float — from around 2.3% in mid-April, when it peaked near 2.4% of float. The CMS moratorium news is precisely the kind of regulatory shock that could flip that trend. Borrow availability remains loose, with cost to borrow running at a benign 0.48% APR and availability well above squeeze territory. The ORTEX short score has also been drifting lower, from 38.3 on May 1 to 34.0 today — a move that reflects the recent covering, not a structural shift in sentiment.
The options market is only mildly cautious. The put/call ratio is running at 0.39, modestly above its 20-day mean of 0.30 but less than one standard deviation away. That is a far cry from defensive positioning. Peers tell a mixed story: ADUS is essentially flat on the week, LFST added 8%, while CSTL fell 24%. Sector noise is high, making AVAH's pre-earnings outperformance harder to read as a clean signal.
The Street has been trimming targets across the board. Truist cut its price target to $8 from $9 in April, maintaining a Hold. Before that, Barclays, RBC, and BMO all lowered targets in March following the prior quarterly print, though all maintained their ratings — Barclays at Overweight with a $9.50 target, BMO at Outperform with a $10 target. The mean target of $9.70 implies roughly 42% upside from the current price of $6.82, but the direction of travel on targets has been uniformly negative since January. The EV/EBITDA multiple has nudged up to 8.4x over the past month, tracking the price recovery, while the P/E of 10.5x reflects modest earnings expectations.
Ownership adds a notable subplot. CEO Jeffrey Shaner sold $1.25 million of stock on both February 18 and 19, part of a broader cluster of C-suite sales totalling around $6.4 million net over the 90-day window through mid-February. Those sales occurred at prices around $7.20–$7.38, above today's level. Vanguard added 1.5 million shares through March-end, and BlackRock added nearly 980,000 through April — both passive-flow additions that provide a structural bid but no directional read on the earnings outcome.
What to watch tomorrow: whether management addresses the CMS registration moratorium directly, and whether the Q1 revenue and Medicaid reimbursement commentary is strong enough to sustain the month's price gains against a freshly complicated regulatory backdrop.
See the live data behind this article on ORTEX.
Open AVAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
